Theraclion's Sonovein® HIFU Platform Achieves Key Chinese Safety Certification, Advancing Toward NMPA Market Authorization
核心洞察
Theraclion's Sonovein® (搜索) robotic platform for non-invasive varicose vein (搜索) treatment has successfully passed China's GB 9706.1-2020 medical electrical equipment safety standard.
The certification validates Sonovein® (搜索)'s compliance with stringent Chinese technical and safety criteria established by the National Medical Products Administration (搜索) (NMPA).
This regulatory milestone represents significant progress toward market authorization in China, one of the world's largest markets for advanced medical technologies.
French MedTech company Theraclion has achieved a critical regulatory milestone for its Sonovein® (搜索) platform, successfully passing China's GB 9706.1-2020 medical electrical equipment safety standard. This certification represents a pivotal step toward market authorization from the National Medical Products Administration (搜索) (NMPA) for the company's robotic High-Intensity Focused Ultrasound (HIFU) system designed for non-invasive varicose vein (搜索) treatment.
Regulatory Breakthrough for HIFU Technology
The GB 9706.1-2020 standard serves as China's national equivalent of the internationally recognized IEC 60601-1 normative framework. Sonovein® (搜索)'s compliance with this standard confirms the platform meets the latest Chinese requirements for electrical safety and focused ultrasound emissions for medical devices, validating the robustness of its design and manufacturing processes.
From a regulatory standpoint, compliance with GB 9706.1-2020 is a pivotal milestone in the NMPA approval pathway, ensuring that Sonovein® (搜索) fulfills one of the core prerequisites for market authorization in China. This achievement demonstrates the platform's ability to meet the stringent technical and safety criteria established by Chinese regulatory authorities.
Clinical Impact and Market Potential
Sonovein® (搜索) represents a significant advancement in varicose vein (搜索) treatment, offering a non-invasive alternative to traditional surgical procedures. The HIFU technology concentrates therapeutic ultrasounds on an internal focal point from outside the body, eliminating the need for incisions or an operating room setting.
The platform has already demonstrated clinical adoption, with more than a dozen centers worldwide incorporating the technology into their practice. To date, Sonovein® (搜索) has been used in over 3,500 procedures, establishing a substantial real-world evidence base for the technology's safety and efficacy.
Strategic Market Expansion
This certification marks significant progress toward market authorization and commercialization in China, described by Theraclion as one of the world's largest and most dynamic markets for advanced medical technologies. The achievement positions Sonovein® (搜索) to advance its international expansion strategy and potentially bring non-invasive ultrasound innovation to a broader patient population.
Theraclion's Sonovein® (搜索) platform holds MDR CE-marking for European markets, though it remains unavailable for sale in the United States. The company estimates that the technology could potentially replace millions of surgical procedures annually, representing a substantial market opportunity for non-invasive varicose vein (搜索) treatment.
Technology Platform Overview
High Intensity Focused Ultrasound (HIFU) technology offers distinct advantages over conventional surgical approaches by eliminating the need for incisions or operating room procedures. The robotic platform design of Sonovein® (搜索) provides precision targeting of therapeutic ultrasounds, concentrating energy on specific treatment areas while preserving surrounding tissue integrity.
With this certification secured, Sonovein® (搜索) remains on track to deliver on its international expansion strategy, potentially transforming the treatment landscape for varicose vein (搜索) patients in one of the world's most significant healthcare markets.